Results 181 to 190 of about 2,285,787 (260)

Impact of cellular composition and T-cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (CAR) T-cells. [PDF]

Transfusion
Vučinić V, Tumewu T, Brückner M, Kirchberg J, Jentzsch M, Buhmann R, Remane Y, Hoffmann S, Ramdohr F, Merz M, Metzeler KH, Schwind S, Herling C, Krauß SM, Herling M, Franke GN, Grieb N, Stachel G, Janz M, Penack O, Bullinger L, Keller U, Cross M, Henschler R, Bach E, Platzbecker U.   +25 more
europepmc   +1 more source

Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies. [PDF]

Cancer Cell Int
Nasiri F, Safarzadeh Kozani P, Salem F, Mahboubi Kancha M, Dashti Shokoohi S, Safarzadeh Kozani P.   +5 more
europepmc   +1 more source

An immune exhaustion signature predicts prognosis and identifies patients with diffuse large B-cell lymphoma (DLBCL) who derive preferential benefit from chimeric antigen receptor (CAR)-T cell therapy. [PDF]

Cancer Pathog Ther
Zheng B, Hu W, Fang Y, Li R.
europepmc   +1 more source

Precision-cut tumor tissue slices, a novel tool to study the tumor microenvironment interactions with chimeric antigen receptor (CAR) T cells. [PDF]

PLoS One
Durante V, Wittwer A, Theek B, Martinez-Osuna M, Donnadieu E, Hardt O, Eckardt D, Bosio A, Schallenberg S, Herbel C.   +9 more
europepmc   +1 more source

Optimal Chimeric Antigen Receptor (CAR)-mRNA for Transient CAR T Cell Generation. [PDF]

Int J Mol Sci
Kitte R, Serfling R, Blache U, Seitz C, Schrader S, Köhl U, Fricke S, Bär C, Tretbar US.   +8 more
europepmc   +1 more source

Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective. [PDF]

RMD Open
Hsieh EWY, Chung JB, Amin A, Askanase AD, Bartok B, Brunetta P, Carrasco-Alfonso MJ, Coney C, Cooper JC, Dall'Era M, Delev N, Eldred A, Furie RA, Garces S, Groover K, Harrington M, Hogan JJ, Imperato GH, Jackson M, Jackson SW, Jongco AM, Karis E, Koegel A, König MF, Koretzky G, Kumar V, Morand E, Payne AS, Popat V, Rizvi N, Rohan P, Sadelain M, Schett G, Singh AP, van Vollenhoven RF, Zack D, Lupus ABC CAR T Working Group.   +36 more
europepmc   +1 more source

The CXCL16/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. [PDF]

Genome Med
Lu IN, Müller-Miny L, Krekeler C, Cheung PF, Antonopoulou G, Jeibmann A, Schulte-Mecklenbeck A, Kerl K, Call S, Reicherts C, Bleckmann A, Stelljes M, Lenz G, Wiendl H, Meyer Zu Hörste G, Grauer OM.   +15 more
europepmc   +1 more source

Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy. [PDF]

Immunooncol Technol
Carcopino C, Erdogan E, Henrich M, Kobold S.   +3 more
europepmc   +1 more source

Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of ovarian cancer. [PDF]

Cancer Cell Int
Boulifa A, Franzén AS, Raftery MJ, Radecke C, Pecher G.   +4 more
europepmc   +1 more source

Identification of Hub Genes and Pathways in Preinfusion Chimeric Antigen Receptor (CAR) T-cell Products Associated With Cytokine Release Syndrome. [PDF]

Cureus
Khalafallah SA, Mohammed Elzein A, Faris IM, Attaelmanan GA, Alamin MF, Almleeh A, Bader M, Alfaki M.   +7 more
europepmc   +1 more source